Diabetic Neuropathy Management

Diagnosis and Screening

The American Diabetes Association recommends that all patients should be assessed for diabetic peripheral neuropathy starting at diagnosis of type 2 diabetes and 5 years after the diagnosis of type 1 diabetes, with annual evaluations thereafter 1, 4
Assessment should include a careful history and evaluation of small-fiber function and large-fiber function 1, 2
Annual 10-g monofilament testing is essential to identify feet at risk for ulceration and amputation 1, 2
Diabetic neuropathy is a diagnosis of exclusion; other causes such as vitamin B12 deficiency, hypothyroidism, and renal disease must be ruled out 4

The American Diabetes Association recommends targeting optimal glycemic control to prevent or delay neuropathy development in type 1 diabetes (Grade A evidence) and slow progression in type 2 diabetes (Grade B evidence) 1, 2
Aim for stable blood glucose levels and avoid extreme fluctuations 5

First-line medications (Grade A evidence) include pregabalin, duloxetine, and gabapentin 1, 2
Tricyclic antidepressants have good efficacy but significant side effects including anticholinergic effects and sedation 5

Identify and treat manifestations of autonomic neuropathy including hypoglycemia unawareness, resting tachycardia, orthostatic hypotension, gastroparesis, and other gastrointestinal symptoms 1, 6
For orthostatic hypotension: ensure adequate salt intake, avoid aggravating medications, use compressive garments, and consider FDA-approved medications like midodrine or droxidopa 6

Regular foot examinations are essential for all patients with diabetic neuropathy to prevent complications 6, 4
Address cardiovascular risk factors including hypertension and hyperlipidemia as part of comprehensive management 3
Failing to rule out other causes of neuropathy before attributing symptoms to diabetes can lead to misdiagnosis 1